Los Angeles Capital Management LLC boosted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 23.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,656 shares of the medical instruments supplier's stock after purchasing an additional 6,320 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.15% of LeMaitre Vascular worth $3,126,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. NBC Securities Inc. grew its holdings in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 183 shares in the last quarter. GAMMA Investing LLC raised its position in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier's stock worth $45,000 after buying an additional 199 shares in the last quarter. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular in the 3rd quarter worth approximately $60,000. West Oak Capital LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $58,000. Finally, nVerses Capital LLC increased its stake in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on LMAT. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company. Lake Street Capital initiated coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They set a "buy" rating and a $105.00 target price for the company. Oppenheimer reiterated an "outperform" rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Finally, JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $94.57.
Check Out Our Latest Research Report on LMAT
LeMaitre Vascular Stock Performance
Shares of NASDAQ:LMAT traded down $0.69 during midday trading on Wednesday, reaching $102.57. The company had a trading volume of 109,022 shares, compared to its average volume of 124,805. LeMaitre Vascular, Inc. has a 1-year low of $50.17 and a 1-year high of $106.49. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 56.05, a price-to-earnings-growth ratio of 2.53 and a beta of 0.89. The company has a fifty day simple moving average of $91.28 and a two-hundred day simple moving average of $85.12.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same quarter last year, the company posted $0.33 EPS. LeMaitre Vascular's revenue for the quarter was up 15.6% on a year-over-year basis. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.
LeMaitre Vascular Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.62%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.
LeMaitre Vascular Profile
(
Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Articles
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
